NEOTHETICS, INC. (NASDAQ:NEOT) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07
(d)Exhibits.
| Exhibit No. | Description |
| 99.1 | Press release, dated January5, 2018. |
-3-
Neothetics, Inc. ExhibitEX-99.1 2 d521526dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 NEOTHETICS ANNOUNCES ADJOURNMENT OF SPECIAL STOCKHOLDERS MEETING TO SOLICIT ADDITIONAL VOTES FOR MERGER WITH EVOFEM SAN DIEGO – January 5,…To view the full exhibit click here
About NEOTHETICS, INC. (NASDAQ:NEOT)
Neothetics, Inc. is a clinical-stage specialty pharmaceutical company, which develops therapeutics. The Company focuses on localized fat reduction and body contouring. It focuses on the development of LIPO-202 for the reduction of central abdominal bulging due to subcutaneous fat in non-obese patients. It has completed Phase II development of LIPO-202. LIPO-202 is administered in a subcutaneous injection procedure that activates a natural metabolic process to shrink fat cells, without killing them, resulting in localized fat reduction, measurable results within four weeks and minimal risk with no downtime. The Company is developing a product candidate, LIPO-102, an injectable form of a combination of salmeterol xinafoate and fluticasone propionate. LIPO-102 is indicated for the treatment of the orphan indication of symptomatic exophthalmos, or protrusion of the eye from the orbit, associated with thyroid-related eye disease caused by the expansion of fat and muscle behind the eye.
